Long-term real-life experience of semaglutide in a monocentric cohort with type 2 diabetes and metabolic dysfuction-associated steatotic liver disease (MASLD)

Conference Reports for NATAP

EASL - European Association
for the Study of the Liver
Barcelona, Spain
May 27-30, 2026


Long-term real-life experience of semaglutide in a monocentric cohort with type 2 diabetes and metabolic dysfuction-associated steatotic liver disease (MASLD)

	EASL 2026 May 26-30 Barcelona Giovanni Petralli 1,